Navigation Links
Amgen Positioned to Deliver Attractive Growth Over Next Five Years
Date:11/7/2008

NEW YORK, Nov. 7 /PRNewswire-FirstCall/ -- At an Amgen (Nasdaq: AMGN) meeting of about 200 securities analysts and investors in New York City today, several members of its senior management team outlined the Company's growth strategy, which includes delivering on its pipeline -- including the experimental bone drug denosumab -- growing in-line products and continuing to pursue operating efficiencies.

"In 2001, Amgen had two blockbuster products and today we have five blockbusters on the market," said Amgen Chairman and CEO Kevin Sharer. "Over the next five years we could have three more drugs achieve blockbuster status: Sensipar(R) (cinacalcet), denosumab for osteoporosis and denosumab for cancer-related indications."

Roger M. Perlmutter, M.D., Ph.D., executive vice president for Research and Development (R&D), noted that increased investment in R&D has more than doubled the size of Amgen's pipeline. In 2001, Amgen had about 20 molecules in the pipeline. In 2008 there are more than 50.

"We are optimistic that our pipeline will deliver a number of innovative products, including denosumab, that will provide important treatments for patients around the world who suffer from grievous illness," Perlmutter said.

Amgen is anticipating 17 key Phase 2 and 3 clinical study results in 2009 and 2010, including for denosumab (oncology), AMG 386 and AMG 655 for various cancer indications, and its Sensipar/Mimpara EVOLVE trial, an outcomes study in dialysis patients. The Company has completed enrollment of most of its denosumab oncology studies and expects to have the opportunity to review data from the first skeletal-related events (SRE) studies in the first half of 2009.

Amgen expects to complete its Biologic License
'/>"/>

SOURCE Amgen
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Amgen and Genentech Brace Themselves for Heavy Pressure From Biogenerics Manufacturers
2. More Than 230 Cyclists to Ride in Amgen California Coast Classic Bike Tour to Raise $1.3 Million for Arthritis Foundation
3. Entry of Biogenerics and Decreasing Use of Amgens Epogen and Johnson & Johnsons Procrit Will Cause a $2.8 Billion Decline in the Drug Market for Chemotherapy-Induced Anemia by 2016
4. Oxford Genome Sciences and Amgen to Jointly Discover Novel Therapeutic Antibodies in Cancer
5. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
6. Co-Inventor of Amgens Aranesp(R) Technology Directs Worldwide Patent Strategy for Diffusion Pharmaceuticals First-in-Class Oxygen Enhancing Therapeutics
7. Amgen Announces Webcast of 2008 Third Quarter Financial Results
8. Amgens Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23
9. Call for Applications: The Amgen Award for Science Teaching Excellence
10. Amgen to Webcast 2008 Business Review Meeting on November 7 From Millennium Hotel in New York
11. New Therapy by Merck is Positioned to Earn Gold-Standard Status by 2011 in the Treatment of Chemotherapy-Induced Nausea and Vomiting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... ST. LOUIS , Dec. 23, 2014 /PRNewswire/ ... announced today that the waiting period under the ... with the acquisition expired on December 22, 2014, ... and review requirement for the acquisition of the ... U.S. antitrust clearance satisfies another condition to ...
(Date:12/22/2014)... , Dec. 22, 2014 /PRNewswire/ - RepliCel Life ... regenerative medicine company focused on the development of autologous ... out of the University of Calgary in conjunction with ... Carolina, which further validates the company,s ongoing clinical research ... effects of pattern baldness. The paper entitled ...
(Date:12/22/2014)... December 22, 2014 ITRA Global, one ... occupiers of commercial real estate, has further expanded its ... in Perth and Brisbane, Western Australia, reports Mylinda Vick, ... , ITRA Global / ACORPP (Australian Corporate Property ... consultancy company providing property services to a wide range ...
(Date:12/19/2014)... 2014 Naurex Inc., a biopharmaceutical company leveraging ... of the central nervous system, today announced that ... will present at the 33 rd annual J.P. ... at 3:00 p.m. PST on Tuesday, January 13, 2015, ... Francisco, Calif. About Naurex ...
Breaking Biology Technology:Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2
... CALGARY, Oct. 2 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") ... agreement with the U.S. Food and Drug Administration (FDA) ... design of a Phase 3 trial examining REOLYSIN in ... head and neck cancers. The SPA is an agreement ...
... ... with their new catalog: pharmaceuticalstability.com , ... Black Mountain, NC (PRWEB) October 2, 2009 -- Parameter Generation ... combined their resources in a new catalog and web site called "Pharmaceutical Stability Solutions". ...
... If a bird collides with a plane the consequences can ... can deform the structure of the aircraft fuselage, causing stresses ... future, sensors in the aircraft skin will detect such damage ... The sensors are light they don,t need any cables ...
Cached Biology Technology:Oncolytics Biotech(R) Inc. Reaches Special Protocol Assessment Agreement with the FDA on Design of Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers 2Oncolytics Biotech(R) Inc. Reaches Special Protocol Assessment Agreement with the FDA on Design of Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers 3Oncolytics Biotech(R) Inc. Reaches Special Protocol Assessment Agreement with the FDA on Design of Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers 4Oncolytics Biotech(R) Inc. Reaches Special Protocol Assessment Agreement with the FDA on Design of Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers 5Parameter Generation and Control Launches New Catalog "Pharmaceutical Stability Solutions" 2Energy-autonomous sensors for aircraft 2
(Date:12/17/2014)... , Dec. 15, 2014 Research and Markets ... addition of the "Samsung Galaxy S5 - ... report to their offering. ... totally different sensing technology than the iPhone 5S, ... sensor in its product. The Galaxy ...
(Date:12/17/2014)... , Dec. 16, 2014  Automation is fundamentally ... more evident than at international borders. Over the ... scanners have allowed veteran travelers to self process ... Control (APC) Kiosks at an increasing number of ... According to Maxine Most ...
(Date:12/11/2014)... Minn. , Dec. 10, 2014  Data ... physiologic monitoring, has released a new series of ... of preclinical toxicology researchers. M series, part of ... toxicologists collect the best possible physiologic data when ... Adding functional endpoints to toxicology studies has ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2New telemetry implants expected to change how large animal toxicology studies are conducted 2
... is investigating whether the board of directors of ... laws as evidenced through alleged inconsistencies in the company,s ... June 15, 2012 are encouraged to contact attorney Hamilton ... rights and remedies. "On March 16, ...
... 25, 2012) The twinkling of fireflies heralds summer ... male fireflies attract females, attention with bioluminescent flashes. ... School of Arts and Sciences, published online in ... reveals that, after the lights go out, female fireflies ...
... pollutants into our waters and atmosphere could soon be ... Presenting their research today, 26 June, in IOP ... Universit de Technologie de Compigne, believe their work ... the exact location where pollutants have been leaked as ...
Cached Biology News:Romancing the firefly 2Romancing the firefly 3Maths formula leads researchers to source of pollution 2
Tight junctions are complexes of proteins that create intercellular boundaries between the plasma membrane domains of epithelial and endothelial cells. Antigen: Synthetic peptide corresponding to...
Polyclonal Antibody to TRIB1/ SKIP1/ Tribbles 1...
TNF-Related Apoptosis Inducing Ligand-Receptor-1...
PMA (YPMA-1)...
Biology Products: